<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04040010</url>
  </required_header>
  <id_info>
    <org_study_id>3. Colostrum &amp; bone</org_study_id>
    <nct_id>NCT04040010</nct_id>
  </id_info>
  <brief_title>The Effects of Bovine Colostrum in Bone Metabolism in Humans</brief_title>
  <official_title>The Effects of Bovine Colostrum in Bone Metabolism in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Petros Dinas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Thessaly</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Osteoporosis constitutes a major public health concern. For instance, in European Union 1 in&#xD;
      3 women and at least 1 in 6 men will suffer an osteoporotic fracture during their lifespan.&#xD;
      The burden of osteoporosis is estimated to raise 25% by 2025. Worldwide, by 2050, the&#xD;
      incidence of osteoporotic fractures is expected to increase 240% in women and 310% in men&#xD;
      compared to 1990. The aforementioned estimates might indicate the existence of some gaps&#xD;
      related to current products on the market for prevention and treatment of osteoporosis.&#xD;
      Actually, the use of the approved pharmacological agents for osteoporosis have been&#xD;
      decreasing in European Union and worldwide. Patients are becoming increasingly reluctant to&#xD;
      take medicines; even those with severe osteoporosis are refusing treatment. Recent published&#xD;
      reports on the matter revealed that patients fear the side effects of current pharmacological&#xD;
      agents. Actually, therapy with bisphosphonates, the most prescribed medication for the&#xD;
      treatment of postmenopausal, glucocorticoid-induced and male osteoporosis has been associated&#xD;
      with severe side effects as osteonecrosis of the jaw and atypical femoral fractures.&#xD;
&#xD;
      Colostrum, a milky substance produced by mammals, known to be responsible for the development&#xD;
      of the immune and skeleton systems of the offspring, has on its constituent's lactoferrin&#xD;
      (LF). This multi-functional protein has been shown to affect both bone resorbing and bone&#xD;
      formation pathways. The safety and tolerance on the use of bovine colostrum in humans&#xD;
      (children and adults) have been well documented; it has a 'Generally Recognized As Safe'&#xD;
      status from the United States Food and Drug Administration. Allergies and lactose&#xD;
      intolerance, which are main shortcomings of milk consumption, have not been reported in&#xD;
      relation to colostrum. Actually, human colostrum and bovine colostrum share the same&#xD;
      bioactive components, but bovine sources are more potent than that of human. In accordance,&#xD;
      bovine colostrum supplementation has been used in several therapeutic applications as&#xD;
      gastrointestinal disorders, allergies and autoimmune diseases, viral and bacterial illnesses,&#xD;
      and HIV-associated immunomodulation HIV. However, the effectiveness of bovine colostrum (as a&#xD;
      whole and not only LF) to reduce bone losses has not been considered yet. Therefore, this&#xD;
      study aims at analyzing the effects of bovine colostrum in diminishing bone mass losses in&#xD;
      humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Postmenopausal women (without any bone condition), osteopenia and osteoporosis patients&#xD;
      (female and male) will be invited to join the study. Participants enrolling the project will&#xD;
      be first measured on the following parameters: 1) general characteristics (age, sex, medical&#xD;
      history); 2) bone mass parameters through Dual-energy X-ray absorptiometry (DXA); 3) bone&#xD;
      formation and resorption markers (alkaline phosphatase, osteocalcin, N-telopeptides and urine&#xD;
      deoxypyridinoline). After measuring the aforementioned parameters, consenting participants&#xD;
      will be randomized into the following groups: Group 1: postmenopausal women taking colostrum&#xD;
      supplementation; Group 2: postmenopausal women taking placebo; Group 3: osteopenia patients&#xD;
      taking colostrum supplementation; Group 4: osteopenia patients taking placebo; Group 5:&#xD;
      osteoporosis patients taking colostrum supplementation; Group 6: osteoporosis patients taking&#xD;
      placebo. Power calculations (90% power, 0.05%) were performed in order to calculate the&#xD;
      sample size needed in each group (considering stratification according to group, a minimum of&#xD;
      7 participants in each group are needed). Following 5 months intervention, participants will&#xD;
      be re-assessed on the following parameters: 1) general characteristics (age, sex, medical&#xD;
      history); 2) bone mass parameters through Dual-energy X-ray absorptiometry (DXA); 3) bone&#xD;
      formation and resorption markers (alkaline phosphatase, osteocalcin, N-telopeptides and urine&#xD;
      deoxypyridinoline).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Actual">February 29, 2020</completion_date>
  <primary_completion_date type="Actual">February 29, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized controlled trial</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of alkaline phosphatase (μg/L)</measure>
    <time_frame>Change from baseline of alkaline phosphatase at five months</time_frame>
    <description>The alkaline phosphatase (μg/L) will be analyzed via human serum samples using an appropriate ELISA kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of osteocalcin (μg/L)</measure>
    <time_frame>Change from baseline of osteocalcin at five months</time_frame>
    <description>The osteocalcin (μg/L) will be analyzed via human serum samples using an appropriate ELISA kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of deoxypyridinoline (mmol/L)</measure>
    <time_frame>Change from baseline of deoxypyridinoline at five months</time_frame>
    <description>The deoxypyridinoline (mmol/L) will be analyzed via human serum samples using an appropriate ELISA kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of C-terminal telopeptide (CTX) (pg/mL)</measure>
    <time_frame>Change from baseline of C-terminal telopeptide at five months</time_frame>
    <description>The C-terminal telopeptide (CTX) (pg/mL) will be analyzed via human serum samples using an appropriate ELISA kit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of bone mineral density (g/cm2)</measure>
    <time_frame>Change from baseline of bone mineral density at five months</time_frame>
    <description>The bone mineral density (g/cm2) will be analyzed via Dual-energy X-ray absorptiometry scan</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change of bone mineral content (gr)</measure>
    <time_frame>Change from baseline of bone mineral content at five months</time_frame>
    <description>The bone mineral content (gr) will be analyzed via Dual-energy X-ray absorptiometry scan</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Osteopenia</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Postmenopausal women colostrum supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoporosis patients colostrum supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteopenia patients colostrum supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Postmenopausal women placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteoporosis patients placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Osteopenia patients placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Colostrum supplementation for bone loss</intervention_name>
    <description>Participants in the interventions groups (i.e. colostrum supplementation) will take a colostrum mixture for 5 months (5 times per week; a total of 250ml per day in liquid form). Participants in the placebo groups (i.e. controls) will be taking a placebo mixture (a total of 250ml per day in liquid form per dose) for the same period of time.</description>
    <arm_group_label>Osteopenia patients colostrum supplement</arm_group_label>
    <arm_group_label>Osteopenia patients placebo</arm_group_label>
    <arm_group_label>Osteoporosis patients colostrum supplement</arm_group_label>
    <arm_group_label>Osteoporosis patients placebo</arm_group_label>
    <arm_group_label>Postmenopausal women colostrum supplement</arm_group_label>
    <arm_group_label>Postmenopausal women placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Postmenopausal women (no menses for the last year at least);&#xD;
&#xD;
          -  Osteoporosis patients (female): T-score&lt;-2.5 at the femoral neck (or other anatomical&#xD;
             site);&#xD;
&#xD;
          -  Osteoporosis patients (male): T-score&lt;-2.5 at the femoral neck (or other anatomical&#xD;
             site)&#xD;
&#xD;
          -  Osteopenia patients (female): T-score&lt;-1.0 at the femoral neck (or other anatomical&#xD;
             site);&#xD;
&#xD;
          -  Osteopenia patients (male): T-score&lt;-1.0 at the femoral neck (or other anatomical&#xD;
             site)&#xD;
&#xD;
          -  Patients taking drugs/ supplements for osteoporosis will be accepted in the study&#xD;
             after going through a wash-up period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women with irregular menses (i.e. with no established menopause)&#xD;
&#xD;
          -  Patients taking medications for other diseases known to interfere with bone metabolism&#xD;
&#xD;
          -  Patients with other chronic diseases (e.g. diabetes)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>FAME Lab, Department of Exercise Science, University of Thessaly</name>
      <address>
        <city>Tríkala</city>
        <state>Thessaly</state>
        <zip>42100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 26, 2019</study_first_submitted>
  <study_first_submitted_qc>July 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Thessaly</investigator_affiliation>
    <investigator_full_name>Petros Dinas</investigator_full_name>
    <investigator_title>Senior Researcher in human physiology</investigator_title>
  </responsible_party>
  <keyword>bone metabolism</keyword>
  <keyword>Postmenopausal women</keyword>
  <keyword>bone markers</keyword>
  <keyword>bovine colostrum</keyword>
  <keyword>DXA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

